An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

NCT ID: NCT05300724

Last Updated: 2025-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-27

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observation period of approximately 3 years (\~144 weeks) for participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-Related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intermediate AMD

Participants with iAMD will be evaluated for the progression of iAMD to more advanced atrophic AMD stages, such as nascent geographic atrophy (nGA) or incomplete retinal pigment epithelium and outer retinal atrophy (iRORA), and subsequently from nGA or iRORA to complete retinal pigment epithelium (cRORA) and outer retinal atrophy or geographic atrophy (GA), on Day 1 and thereafter every 12 weeks up to the end of the Observation Period, approximately 3 years.

No intervention

Intervention Type OTHER

No intervention will be administered in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention will be administered in this study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, during the study for at least 28 days after the last fluorescein injection for the fluorescein angiography (FA) administration
* Study eye: High-risk intermediate AMD

Exclusion Criteria

* Macular disease in either eye with subretinal deposits not typical of AMD
* Pigmentary abnormalities of the retina in either eye not typical of AMD
* Atrophy in either eye due to causes other than AMD
* Study eye: Any concurrent or history of ocular or intraocular condition
* Study eye: Intraocular surgery, including cataract surgery, within 3 months prior to Day 1
* Study eye: Retinal tears or peripheral retinal breaks within 3 months prior to Day 1
* Study eye: Concurrent or history of retinal laser photocoagulation or anti-vascular endothelial growth factor (anti-VEGF) treatment for exudative MNV, diabetic macular edema, retinal vein occlusion, or proliferative diabetic retinopathy
* Study eye: Presence of choroidal nevus with overlying drusen in the circle with a radius 3600 micrometer centered on the fovea
* Study eye: Previous participation in interventional clinical trials for GA or early stages of AMD, except for vitamins and minerals, regardless of the route of administration within the last 6 months, except for sham-arm participants
* Study eye: History of glaucoma surgery, corneal transplant, retinal pigment epithelium tear, retinal tear that involves the macula, retinal detachment
* Either eye: Uncontrolled progressive glaucoma
* Either eye: Moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy
* Either eye: History of recurrent infectious or inflammatory ocular disease
* Any concurrent or history of taking medications that can induce retinal toxicity
Minimum Eligible Age

50 Years

Maximum Eligible Age

94 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genentech, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Retina Partners of Northwest Arkansas, PLLC

Springdale, Arkansas, United States

Site Status

The Retina Partners

Encino, California, United States

Site Status

Retina Consultants of Orange County

Fullerton, California, United States

Site Status

Northern California Retina Vitreous Associates

Mountain View, California, United States

Site Status

Retina Consultants, San Diego

Poway, California, United States

Site Status

UC Davis Eye Center

Sacramento, California, United States

Site Status

Retinal Consultants Medical Group

Sacramento, California, United States

Site Status

Bay Area Retina Associates

Walnut Creek, California, United States

Site Status

Southwest Retina Consultants

Durango, Colorado, United States

Site Status

Eye Care Center of Northern Colorado PC

Longmont, Colorado, United States

Site Status

Advanced Research

Coral Springs, Florida, United States

Site Status

Rand Eye Institute

Deerfield Beach, Florida, United States

Site Status

National Ophthalmic Research Institute

Fort Myers, Florida, United States

Site Status

Florida Eye Associates

Melbourne, Florida, United States

Site Status

Southeast Retina Center

Augusta, Georgia, United States

Site Status

University Retina and Macula Associates, PC

Oak Forest, Illinois, United States

Site Status

Raj K. Maturi, MD PC

Indianapolis, Indiana, United States

Site Status

Wolfe Eye Clinic

West Des Moines, Iowa, United States

Site Status

Cumberland Valley Retina Consultants PC

Hagerstown, Maryland, United States

Site Status

New England Retina Consultants

Springfield, Massachusetts, United States

Site Status

Foundation for Vision Research

Grand Rapids, Michigan, United States

Site Status

Deep Blue Retina Clinical Research

Southaven, Mississippi, United States

Site Status

Sierra Eye Associates

Reno, Nevada, United States

Site Status

Eye Associates of New Mexico

Albuquerque, New Mexico, United States

Site Status

Vitreous Retina Macula Consultants of New York

New York, New York, United States

Site Status

Ophthalmic Consultants of Long Island

Rockville Centre, New York, United States

Site Status

Duke Eye Center

Durham, North Carolina, United States

Site Status

Cleveland Clinic Cole Eye Institute

Cleveland, Ohio, United States

Site Status

Retina Vitreous Center

Edmond, Oklahoma, United States

Site Status

EyeHealth Northwest

Portland, Oregon, United States

Site Status

Casey Eye Institute - OHSU

Portland, Oregon, United States

Site Status

Erie Retinal Surgery

Erie, Pennsylvania, United States

Site Status

Scheie Eye Institute

Philadelphia, Pennsylvania, United States

Site Status

Palmetto Retina Center, LLC

West Columbia, South Carolina, United States

Site Status

Tennessee Retina PC

Nashville, Tennessee, United States

Site Status

W Texas Retina Consultants PA

Abilene, Texas, United States

Site Status

Austin Retina Associates

Austin, Texas, United States

Site Status

Austin Clinical Research LLC

Austin, Texas, United States

Site Status

Retina Consultants of Texas

Bellaire, Texas, United States

Site Status

Retina Foundation of the Southwest

Dallas, Texas, United States

Site Status

Retina Specialists

DeSoto, Texas, United States

Site Status

San Antonio Eye Center

San Antonio, Texas, United States

Site Status

Rocky Mountain Retina

Salt Lake City, Utah, United States

Site Status

Wagner Kapoor Institute

Norfolk, Virginia, United States

Site Status

Spokane Eye Clinical Research

Spokane, Washington, United States

Site Status

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Site Status

Marsden Eye Specialists

Parramatta, New South Wales, Australia

Site Status

Sydney Retina Clinic and Day Surgery

Sydney, New South Wales, Australia

Site Status

Adelaide Eye and Retina Centre

Adelaide, South Australia, Australia

Site Status

Centre For Eye Research Australia

East Melbourne, Victoria, Australia

Site Status

The Lions Eye Institute

Nedlands, Western Australia, Australia

Site Status

Centre Hospitalier Intercommunal

Créteil, , France

Site Status

Centre Ophtalmologique Pole Vision

Écully, , France

Site Status

CHU de GRENOBLE

Grenoble, , France

Site Status

Hôpital de La Croix Rousse

Lyon, , France

Site Status

Centre Ophtalmologique Maison-Rouge

Strasbourg, , France

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Universitätsklinikum Freiburg

Freiburg im Breisgau, , Germany

Site Status

University Medicine Gottingen Germany

Göttingen, , Germany

Site Status

Medizinische Hochschule Hannover, Innere Abteilung/Pneumologie

Hanover, , Germany

Site Status

Universitatsklinikum Leipzig

Leipzig, , Germany

Site Status

Universitatsklinikum Munster

Münster, , Germany

Site Status

Augenzentrum am St Franziskus-Hospital

Münster, , Germany

Site Status

Universitatsklinikum Tubingen

Tübingen, , Germany

Site Status

Rambam Medical Center - PPDS

Haifa, , Israel

Site Status

Tel Aviv Sourasky Medical Center PPDS

Jerusalem, , Israel

Site Status

Hadassah Medical Center

Jerusalem, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Azienda Sanitaria Universitaria Friuli Centrale ? PO Universitario Santa Maria della Misericordia

Udine, Friuli Venezia Giulia, Italy

Site Status

Fondazione G.B. Bietti Per Lo Sudio E La Ricerca In Oftalmologia-Presidio Ospedaliero Britannico

Rome, Lazio, Italy

Site Status

Ospedale S. Giuseppe Multimedica

Milan, Lombardy, Italy

Site Status

Ospedale San Raffaele S.r.l. - PPDS

Milan, Lombardy, Italy

Site Status

ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco

Milan, Lombardy, Italy

Site Status

Emanuelli Research and Development Center LLC

Arecibo, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia France Germany Israel Italy Puerto Rico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-000046-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GE43220

Identifier Type: -

Identifier Source: org_study_id